Literature DB >> 21839027

The von Willebrand factor from basic mechanisms to clinical practice.

Augusto B Federici.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21839027      PMCID： PMC3159914          DOI： 10.2450/2011.001S

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  16 in total

Review 1.  Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.

Authors:  W Kreuz; C Escuriola-Ettingshausen; I Martinez-Saguer; M Kaiml; B Kornhuber
Journal:  Vox Sang       Date:  1999       Impact factor: 2.144

2.  Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

Authors:  M Gensana; C Altisent; J A Aznar; P Casaña; F Hernández; J I Jorquera; M Magallón; M Massot; L Puig
Journal:  Haemophilia       Date:  2001-07       Impact factor: 4.287

Review 3.  Von Willebrand's disease: clinical management.

Authors:  A B Federici; G Castaman; A Thompson; E Berntorp
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

4.  Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.

Authors:  D Lillicrap; M C Poon; I Walker; F Xie; B A Schwartz
Journal:  Thromb Haemost       Date:  2002-02       Impact factor: 5.249

5.  A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

Authors:  M Jacquemin; A Benhida; K Peerlinck; B Desqueper; L Vander Elst; R Lavend'homme; R d'Oiron; R Schwaab; M Bakkus; K Thielemans; J G Gilles; J Vermylen; J M Saint-Remy
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

6.  Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.

Authors:  T Suzuki; M Arai; K Amano; K Kagawa; K Fukutake
Journal:  Thromb Haemost       Date:  1996-11       Impact factor: 5.249

Review 7.  Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.

Authors:  A Coppola; C Santoro; A Tagliaferri; M Franchini; G DI Minno
Journal:  Haemophilia       Date:  2010-01       Impact factor: 4.287

8.  Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.

Authors:  J Cox Gill; B M Ewenstein; A R Thompson; G Mueller-Velten; B A Schwartz
Journal:  Haemophilia       Date:  2003-11       Impact factor: 4.287

9.  Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.

Authors:  Massimo Franchini; Gina Rossetti; Annarita Tagliaferri; Corrado Pattacini; Donatella Pozzoli; Giuseppe Lippi; Franco Manzato; Daniela Bertuzzo; Giorgio Gandini
Journal:  Haematologica       Date:  2003-11       Impact factor: 9.941

10.  Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.

Authors:  Augusto B Federici; Giancarlo Castaman; Massimo Franchini; Massimo Morfini; Ezio Zanon; Antonio Coppola; Annarita Tagliaferri; Elio Boeri; Maria Gabriella Mazzucconi; Gina Rossetti; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2007-07       Impact factor: 9.941
View more
  2 in total

Review 1.  From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.

Authors:  Larisa Anghel; Radu Sascău; Rodica Radu; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

Review 2.  Endothelium, Platelets, and Coagulation Factors as the Three Vital Components for Diagnosing Bleeding Disorders: A Simplified Perspective with Clinical Relevance.

Authors:  Abhinav Bhattarai; Sangam Shah; Sara Bagherieh; Omid Mirmosayyeb; Sangharsha Thapa; Sandip Paudel; Pawan Gyawali; Pitambar Khanal
Journal:  Int J Clin Pract       Date:  2022-08-27       Impact factor: 3.149
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.